BOSTON, October 30, 2014 – The Joslin Institute for Technology Translation (JITT) today announced that three Johnson & Johnson Diabetes Solutions Companies, LifeScan, Inc., Animas Corporation and Calibra Medical, Inc., have joined JITT as Founding Members and as members of JITT’s Advisory Board. JITT, a recently introduced innovation group of Joslin Diabetes Center, is focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes.

“We are pleased to welcome the Johnson & Johnson Diabetes Solutions Companies as Founding Members of JITT.  Their commitment to developing and offering meaningful products to improve diabetes care around the world makes them ideal contributors to JITT,”   said John L. Brooks III, President and CEO of Joslin Diabetes Center.  “We look forward to working closely with them as well as with our other Founding Members to provide further insight to clinical solutions that will impact diabetes-related technologies and allow for further advancement of decision support tools as we make strides into digital health.”

“It is very exciting to have the Johnson & Johnson Diabetes Solutions Companies on board,” said Harry Mitchell, Executive Director of JITT. “We look forward to collaborating with them on clinical solutions to improve patient care and utilizing their international presence to help JITT further its mission.”

“Our vision is to create a world without limits for people with diabetes,” said Val Asbury, President, LifeScan, Inc., part of the Johnson & Johnson family of companies.   “We are honored to join with the Joslin Institute for Technology Translation to further accelerate the development of innovative patient-centric solutions to improve diabetes care and outcomes.”

Joslin Diabetes Center does not promote or endorse any product. Revenue and fees received by JITT will be invested in digital health to improve patient care.

###

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment